---
title: The current landscape of frontline large B-cell lymphoma trials
date: '2024-09-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39316716/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240925194758&v=2.18.0.post9+e462414
source: Blood
description: At least 25-35% of patients with large B cell lymphoma (LBCL) are not
  cured with frontline treatment, with generally poor subsequent outcomes. This motivates
  ongoing and intense interest in improving the frontline treatment of this disease.
  R-CHOP has remained the standard of care for 20 years despite dozens of trials aiming
  to improve upon this regimen, and only recently has a novel regimen (Pola-R-CHP)
  challenged its supremacy. Fortunately, at least 15 promising randomized trials ...
disable_comments: true
---
At least 25-35% of patients with large B cell lymphoma (LBCL) are not cured with frontline treatment, with generally poor subsequent outcomes. This motivates ongoing and intense interest in improving the frontline treatment of this disease. R-CHOP has remained the standard of care for 20 years despite dozens of trials aiming to improve upon this regimen, and only recently has a novel regimen (Pola-R-CHP) challenged its supremacy. Fortunately, at least 15 promising randomized trials ...